Exploring an Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes

Gain multidisciplinary expert insights on the latest approved AML therapies to improve the care of patients with newly diagnosed or relapsed/refractory disease with these downloadable slides and on-demand Webcast of a CCO/NCCN Webinar.

Share

Program Content

Activities

AML Without Targetable Tx
Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

AML With Targetable Tx
Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

New Therapies in AML
New and Novel Advances in AML Therapeutics
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

<i>EP</i>: AML Expert Guidance
ExpressPoints
Exploring an Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 23, 2021

Expires: June 22, 2022

Faculty

cover img faculity

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

cover img faculity

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Supporters

Supported by educational grants from

AbbVie Inc.

Astellas Pharma US

Pfizer, Inc.

Servier Pharmaceuticals